The aims of the proposed research are to critically evaluate, compare and validate selected multi-modality imaging metrics as quantitative (surrogate) biomarkers of the response of breast tumors to specific treatments to provide the scientific basis for their translation into patient management and clinical trials. Recent years have seen a dramatic increase in the range of information available from imaging methods so that a number of techniques are available to quantitatively monitor tumor growth and treatment response. Several of these have been used in both pre-clinical and clinical studies, but with mixed results confounded by lack of standardization, inadequate understanding of underlying mechanisms and absence of appropriate validation to assist their interpretation. We propose to systematically evaluate emerging, clinically-viable imaging metrics in appropriate animal models to establish which combination of methods is most accurate at predicting response to specific treatments that are relevant for breast cancer. The paradigm we have chosen to achieve these ends considers two major categories of human breast cancer, HER2 positive tumors and ER/PR/HER2 triple-negative tumors and both established and emerging therapies. For each category we will assess treatment response by performing longitudinal studies that combine PET, SPECT, and MRI to provide functional assessments of the response of breast tumors to treatment. We will also correlate imaging with histology data to understand the mechanistic underpinnings of the information provided by each type of measurement. We hypothesize that treatment type will determine which imaging metrics are most sensitive to early response. To test this hypothesis we will pursue the following specific aims: 1. [HER2+ cancer] In the BT-474 mouse model of breast cancer with and without resistance to Herceptin (to simulate responders and nonresponders, respectively), measure the effects of treatment response to Herceptin or Herceptin+lapatinib as reported by PET, SPECT, and MRI metrics. This study will also be performed in the polymoma middle T (PyMT) spontaneous mouse model of human breast cancer. 2. [Triple negative cancer] In the MDA-231 mouse model of triple-negative breast cancer with and without resistance to Docetaxel (to simulate responders and nonresponders, respectively), measure the effects of treatment to Docetaxel or Docetaxel+sunitinib as reported by PET, SPECT, and MRI metrics.
We propose to systematically evaluate emerging clinically-viable imaging metrics to establish which methods are most accurate at predicting treatment response with clinically employed breast cancer treatments. In this way we hope to expand the range of quantitative imaging biomarkers that can be implemented in the clinical setting. We hypothesize that treatment type will determine which imaging metrics are the most sensitive to early response enabling specific treatment classes to be paired with specific imaging approaches so that the most sensitive imaging biomarkers can be selected when designing clinical trials.
|Jarrett, Angela M; Lima, Ernesto A B F; Hormuth 2nd, David A et al. (2018) Mathematical models of tumor cell proliferation: A review of the literature. Expert Rev Anticancer Ther 18:1271-1286|
|McKenna, Matthew T; Weis, Jared A; Quaranta, Vito et al. (2018) Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. Ann Biomed Eng 46:899-911|
|Woodall, Ryan T; Barnes, Stephanie L; Hormuth 2nd, David A et al. (2018) The effects of intravoxel contrast agent diffusion on the analysis of DCE-MRI data in realistic tissue domains. Magn Reson Med 80:330-340|
|Syed, Anum K; Woodall, Ryan; Whisenant, Jennifer G et al. (2018) Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer. Neoplasia 21:17-29|
|Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2018) Biophysical Modeling of In Vivo Glioma Response After Whole-Brain Radiation Therapy in a Murine Model of Brain Cancer. Int J Radiat Oncol Biol Phys 100:1270-1279|
|Joint Head and Neck Radiotherapy-MRI Development Cooperative (2018) Dynamic contrast-enhanced magnetic resonance imaging for head and neck cancers. Sci Data 5:180008|
|Hormuth 2nd, David A; Weis, Jared A; Barnes, Stephanie L et al. (2017) A mechanically coupled reaction-diffusion model that incorporates intra-tumoural heterogeneity to predict in vivo glioma growth. J R Soc Interface 14:|
|Lima, E A B F; Oden, J T; Wohlmuth, B et al. (2017) Selection and Validation of Predictive Models of Radiation Effects on Tumor Growth Based on Noninvasive Imaging Data. Comput Methods Appl Mech Eng 327:277-305|
|Joint Head and Neck Radiotherapy-MRI Development Cooperative (2017) A Multi-Institutional Comparison of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameter Calculations. Sci Rep 7:11185|
|Sorace, Anna G; Syed, Anum K; Barnes, Stephanie L et al. (2017) Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. Mol Imaging Biol 19:130-137|
Showing the most recent 10 out of 51 publications